Comparative Pharmacology
Head-to-head clinical analysis: EDURANT PED versus ETRAVIRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDURANT PED versus ETRAVIRINE.
EDURANT PED vs ETRAVIRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Edurant PED is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1. It binds to reverse transcriptase, causing a conformational change that inhibits the enzyme's RNA-dependent and DNA-dependent DNA polymerase activities, thereby blocking viral replication.
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing allosteric inhibition of RNA-dependent and DNA-dependent DNA polymerase activities.
25 mg orally once daily with a meal.
400 mg orally twice daily after meals.
None Documented
None Documented
Terminal elimination half-life is approximately 50 hours (range 34-73 h). This long half-life supports once-daily dosing and allows for sustained plasma concentrations.
Clinical Note
moderateEtravirine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Etravirine."
Clinical Note
moderateEtravirine + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Etravirine."
Clinical Note
moderateEtravirine + Cyclosporine
"The serum concentration of Cyclosporine can be increased when it is combined with Etravirine."
Clinical Note
moderateEtravirine + Fluconazole
Terminal elimination half-life approximately 41 hours (range 20-70 hours) following multiple doses; supports once-daily dosing with a pharmacokinetic booster (e.g., ritonavir or cobicistat).
Rilpivirine is primarily metabolized by CYP3A4; after oral administration, approximately 85% of the dose is recovered in feces (mainly as unchanged drug and metabolites) and 6% in urine. Less than 1% is excreted unchanged in urine.
Fecal: ~93.7% (unchanged drug and metabolites; bile is the major route); Renal: ~1.2% (urinary, negligible unchanged drug).
Category C
Category C
NNRTI Antiretroviral
NNRTI Antiretroviral
"The serum concentration of Fluconazole can be increased when it is combined with Etravirine."